NO20070827L - Farmasoytiske formuleringer inneholdende en blodplateaggregregeringsinnhibitor og et fibrat. - Google Patents
Farmasoytiske formuleringer inneholdende en blodplateaggregregeringsinnhibitor og et fibrat.Info
- Publication number
- NO20070827L NO20070827L NO20070827A NO20070827A NO20070827L NO 20070827 L NO20070827 L NO 20070827L NO 20070827 A NO20070827 A NO 20070827A NO 20070827 A NO20070827 A NO 20070827A NO 20070827 L NO20070827 L NO 20070827L
- Authority
- NO
- Norway
- Prior art keywords
- fibrate
- platelet aggregation
- aggregation inhibitor
- cerebral
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04291896A EP1621200A1 (en) | 2004-07-26 | 2004-07-26 | Pharmaceutical combinations containing an inhibitor of platelet aggregation and a fibrate |
PCT/EP2005/053603 WO2006010748A1 (en) | 2004-07-26 | 2005-07-25 | Pharmaceutical combinations containing an inhibitor of platelet aggregation and a fibrate |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20070827L true NO20070827L (no) | 2007-02-13 |
Family
ID=34931285
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20070827A NO20070827L (no) | 2004-07-26 | 2007-02-13 | Farmasoytiske formuleringer inneholdende en blodplateaggregregeringsinnhibitor og et fibrat. |
Country Status (8)
Country | Link |
---|---|
US (1) | US20090062240A1 (ja) |
EP (2) | EP1621200A1 (ja) |
JP (1) | JP2008507574A (ja) |
CN (1) | CN1988910A (ja) |
AU (1) | AU2005266310B2 (ja) |
CA (1) | CA2574920A1 (ja) |
NO (1) | NO20070827L (ja) |
WO (1) | WO2006010748A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO20075628L (no) * | 2005-04-08 | 2007-11-05 | Bgp Products Ireland Ltd | Farmasøytiske formuleringer |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007106912A2 (en) * | 2006-03-16 | 2007-09-20 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peroxisome-proliferator activated receptor-alpha agonists for organ preservation |
US8211947B2 (en) * | 2008-01-28 | 2012-07-03 | Guillermo Selman-Housein Sosa | Composition and method for treating and preventing musculoskeletal and connective tissue disorders |
FR2932387B1 (fr) * | 2008-06-16 | 2010-09-17 | Cll Pharma | Composition orale contenant un agent anti-plaquettaire de la famille des thienopyridines sous forme de base. |
KR101455446B1 (ko) * | 2008-09-19 | 2014-10-27 | 액티버스 파마 컴퍼니 리미티드 | 의료용 복합 유기 화합물 분체, 그 제조 방법 및 현탁액 |
WO2011076401A1 (de) | 2009-12-23 | 2011-06-30 | Holger Schankin | Acetylsalicylsäure-haltige, im wesentlichen wasserfreie pharmazeutische zusammensetzungen |
CN101985038A (zh) * | 2010-11-08 | 2011-03-16 | 北京阜康仁生物制药科技有限公司 | 一种用于抗血栓的药物组合物 |
CN101985042A (zh) * | 2010-11-08 | 2011-03-16 | 北京阜康仁生物制药科技有限公司 | 一种用于抗血栓的药物组合物 |
CN101984969A (zh) * | 2010-11-08 | 2011-03-16 | 北京阜康仁生物制药科技有限公司 | 含有氯吡格雷和贝特类化合物的药物组合物 |
CA3027462A1 (en) | 2016-06-28 | 2018-01-04 | Asamedic As | Two-component composition |
JP6420923B1 (ja) * | 2017-04-03 | 2018-11-07 | 興和株式会社 | 医薬 |
EP3501522A1 (en) | 2017-12-22 | 2019-06-26 | Asamedic AS | Compositions comprising acetylsalicylic acid and a phosphate salt |
EP3501523A1 (en) | 2017-12-22 | 2019-06-26 | Asamedic AS | Two-component compositions comprising acetyl salicylic acid and a carbonate salt |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2627696B1 (fr) * | 1988-02-26 | 1991-09-13 | Fournier Innovation Synergie | Nouvelle forme galenique du fenofibrate |
AU660852B2 (en) * | 1992-11-25 | 1995-07-06 | Elan Pharma International Limited | Method of grinding pharmaceutical substances |
US5336507A (en) * | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
TW384224B (en) * | 1994-05-25 | 2000-03-11 | Nano Sys Llc | Method of preparing submicron particles of a therapeutic or diagnostic agent |
US5718388A (en) * | 1994-05-25 | 1998-02-17 | Eastman Kodak | Continuous method of grinding pharmaceutical substances |
US5665331A (en) * | 1995-01-10 | 1997-09-09 | Nanosystems L.L.C. | Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers |
US5662883A (en) * | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
US5560932A (en) * | 1995-01-10 | 1996-10-01 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents |
US5534270A (en) * | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
US5510118A (en) * | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
US5543133A (en) * | 1995-02-14 | 1996-08-06 | Nanosystems L.L.C. | Process of preparing x-ray contrast compositions containing nanoparticles |
TW438784B (en) * | 1997-08-29 | 2001-06-07 | Ssp Co Ltd | Triazole derivative or salt thereof and pharmaceutical composition for treating mycosis containing the same |
US6811786B1 (en) * | 1999-04-01 | 2004-11-02 | Ganeden Biotech, Inc. | Methods for reducing cholesterol using Bacillus coagulans spores, systems and compositions |
US6410545B2 (en) * | 1998-07-30 | 2002-06-25 | Parker Hughes Institute | Lipid lowering quinazoline dietary supplement composition |
US6509348B1 (en) * | 1998-11-03 | 2003-01-21 | Bristol-Myers Squibb Company | Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination |
US6201028B1 (en) * | 1998-12-08 | 2001-03-13 | The Rockefeller University | Methods and compositions for prevention and treatment of atherosclerosis and hyperlipidemia with non-steroidal anti-inflammatory drugs |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US20030235595A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent |
US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
AU2001265094A1 (en) * | 2000-06-01 | 2001-12-11 | Merck And Co., Inc. | Pyrazinone thrombin inhibitors |
US20030224058A1 (en) * | 2002-05-24 | 2003-12-04 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
BR0114701A (pt) * | 2000-10-26 | 2003-11-18 | Fournier Lab Ireland Ltd | Combinação de fenofibrato e coenzima q 10 para tratamento de disfunção endotelial |
AU2002302003B2 (en) * | 2001-11-28 | 2008-05-22 | Cardanal Pty Ltd | Method and system for processing electrocardial signals |
WO2008008692A2 (en) * | 2006-07-10 | 2008-01-17 | The General Hospital Corporation | Method and apparatus for detection and treatment of autonomic system imbalance |
-
2004
- 2004-07-26 EP EP04291896A patent/EP1621200A1/en not_active Withdrawn
-
2005
- 2005-07-25 AU AU2005266310A patent/AU2005266310B2/en not_active Ceased
- 2005-07-25 CN CNA2005800253536A patent/CN1988910A/zh active Pending
- 2005-07-25 US US11/658,501 patent/US20090062240A1/en not_active Abandoned
- 2005-07-25 EP EP05769894A patent/EP1778247A1/en not_active Withdrawn
- 2005-07-25 WO PCT/EP2005/053603 patent/WO2006010748A1/en active Application Filing
- 2005-07-25 CA CA002574920A patent/CA2574920A1/en not_active Abandoned
- 2005-07-25 JP JP2007523071A patent/JP2008507574A/ja active Pending
-
2007
- 2007-02-13 NO NO20070827A patent/NO20070827L/no not_active Application Discontinuation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO20075628L (no) * | 2005-04-08 | 2007-11-05 | Bgp Products Ireland Ltd | Farmasøytiske formuleringer |
NO343548B1 (no) * | 2005-04-08 | 2019-04-01 | Bgp Products Ireland Ltd | Farmasøytiske formuleringer |
Also Published As
Publication number | Publication date |
---|---|
AU2005266310B2 (en) | 2011-04-21 |
JP2008507574A (ja) | 2008-03-13 |
CN1988910A (zh) | 2007-06-27 |
AU2005266310A1 (en) | 2006-02-02 |
EP1778247A1 (en) | 2007-05-02 |
EP1621200A1 (en) | 2006-02-01 |
US20090062240A1 (en) | 2009-03-05 |
CA2574920A1 (en) | 2006-02-02 |
WO2006010748A1 (en) | 2006-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20070827L (no) | Farmasoytiske formuleringer inneholdende en blodplateaggregregeringsinnhibitor og et fibrat. | |
Bruno et al. | Progress in 5H [1] benzopyrano [4, 3-d] pyrimidin-5-amine series: 2-methoxy derivatives effective as antiplatelet agents with analgesic activity | |
TW418206B (en) | Isothiazolones | |
NO20072986L (no) | 3-fenyl-pyrazol derivater som modulatorer til 5-HT2A serotoninreseptor anvendelig for behandling av forstyrrelser relatert dertil | |
NO20045557L (no) | Kombinasjon av en DPP IV inhibitor og en kardiovaskulaer forbindelse | |
WO2004020410A3 (en) | Dihydropyridinone derivatives as hne inhibitors | |
RS51645B (en) | 4-FLUORO-N-INDAN-2-ILBENZAMIDE AND ITS USE AS PHARMACEUTICALS | |
Coy et al. | COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans | |
WO2008016522A3 (en) | Hiv reverse transcriptase inhibitors | |
NO20072978L (no) | Nye betuinderivater, preparat derav og anvendelse derav | |
AR056008A1 (es) | Derivados de pirazina antagonistas del receptor a2b de adenosina | |
NO20064295L (no) | Bruk av metylenamidderivater i kardiovaskulaere lidelser | |
Bandgar et al. | Design, synthesis, characterization and biological evaluation of novel pyrazole integrated benzophenones | |
NO20090862L (no) | 2-fenyl-indoler som prostaglandin D2-reseptorantagonister | |
DK1513519T3 (da) | Anvendelse af substituerede cyanopyrrolidiner til behandling af hyperlipidæmi | |
UY29239A1 (es) | Nuevos derivados de piridotienopirimidina | |
TNSN04237A1 (en) | N- ((3-oxo2, 3-dihydro-1h-isoindol-1-yl) acetyl) guanidine derivatives as nhe-1 inhibitors for the treatment of infarction and angina pectoris | |
Chowdhury et al. | Synthesis and biological evaluation of salicylic acid and N-acetyl-2-carboxybenzenesulfonamide regioisomers possessing a N-difluoromethyl-1, 2-dihydropyrid-2-one pharmacophore: dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity | |
Nam et al. | Design and synthesis of 4-quinolinone 2-carboxamides as calpain inhibitors | |
NO20041732L (no) | Anvendelse av irbesartan for fremstilling av medikamenter som anvendes for a forhindre eller behandle pulmonal hypertensjon | |
Abdellatif et al. | A diazen-1-ium-1, 2-diolated nitric oxide donor ester prodrug of 3-(4-hydroxymethylphenyl)-4-(4-methanesulfonylphenyl)-5H-furan-2-one: Synthesis, biological evaluation and nitric oxide release studies | |
Hsieh et al. | The evaluation and structure–activity relationships of 2-benzoylaminobenzoic esters and their analogues as anti-inflammatory and anti-platelet aggregation agents | |
ES2314457T3 (es) | Asociacion de un antagonista de los receptores tp y de clopidogrel. | |
ATE108788T1 (de) | Phenylalkanolsäureester. | |
Ezwaie | The Beneficial Effects of Aspirin in Cardiovascular Disease Prevention |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |